It explains the State Farm agent experience with a flow chart of agent progression through the program, and includes agent testimonials. The brochure does not include any test questions, but the website may be used to find local agents who may be willing to share some tips.
The secondary objectives are safety profile and the response rate. Lapatinib, an oral inhibitor of EGFR and HER2, have been shown to be an effective treatment in HER2/neu overexpressing metastatic breast cancer patient who refractory herceptin, taxane, and anthracycline treatment.
TYKERB is the trade name for lapatinib. In some cases, health care professionals may use the trade name TYKERB when referring to the generic drug name lapatinib. Drug type: Lapatinib is a targeted therapy. Lapatinib is classified as a signal transduction inhibitor - tyrosine kinase inhibitor, inhibitor of EGFR and HER2.